The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

November 19, 2020

In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.

November 19, 2020

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

November 06, 2020

In our exclusive interview, Debu Tripathy, MD, considers the biological and long-term outcome variability of HR-positive, HER2-negative breast cancer and details the research that is being done to develop personalized treatment approaches.

October 29, 2020

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

October 28, 2020

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

October 26, 2020

PLX8394, a next-generation BRAF inhibitor, in combination with cobicistat was found to demonstrate encouraging clinical activity with an acceptable safety profile in patients with BRAF-mutated, refractory solid tumors.

October 22, 2020

In a special episode of OncLive On AirTM Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in TMB-high solid tumors and addressed the controversy surrounding the approval.

October 19, 2020

Lucia Masarova, MD, discusses future research ​efforts in myeloproliferative neoplasms.

October 15, 2020

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

October 15, 2020

In our exclusive interview, Guillermo Garcia-Manero, MD, discusses the prevalence of TP53 mutations in myelodysplastic syndromes and acute myeloid leukemia, the prognosis these mutations confer, and the development of eprenetapopt and magrolimab in this patient population.

October 15, 2020

The addition of the histone deacetylase inhibitor vorinostat to the mTOR inhibitors sirolimus or everolimus demonstrated encouraging clinical activity and manageable safety in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

October 15, 2020

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

October 08, 2020

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

October 08, 2020

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

October 08, 2020

In our exclusive interview, Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in tumor mutational burden–high solid tumors, shares the “transformative importance” of the regulatory decision, and speaks to the controversy surrounding the approval.

October 06, 2020

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

October 05, 2020

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.

September 30, 2020

Isabella C. Glitza Oliva, MD, PhD, MS, discusses ​the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

September 21, 2020

In our exclusive interview, Dr. Tripathy discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.

September 17, 2020

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.